We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

75 hedge funds and large institutions have $494M invested in Epizyme, Inc in 2014 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 31 increasing their positions, 16 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 6

94% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 16

53% more capital invested

Capital invested by funds: $323M → $494M (+$171M)

27% more funds holding

Funds holding: 5975 (+16)

7% more call options, than puts

Call options by funds: $876K | Put options by funds: $815K

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
75
Holders Change
+16
Holders Change %
+27.12%
% of All Funds
2.16%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
22
Increased
31
Reduced
16
Closed
6
Calls
$876K
Puts
$815K
Net Calls
+$61K
Net Calls Change
+$61K

EPZM Hedge Fund Activity: Q1 2014 in Review

75 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q1 2014, worth a combined $494M — up 53% from $323M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new EPZM positions and 6 closed out — a net gain of 16 holders — while 31 added to existing stakes and 16 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $53.1M. The largest seller was MPM Asset Management, cutting an estimated $14.1M.

  • 75 institutional investors held Epizyme, Inc (EPZM) as of Q1 2014, up from 59 in Q4 2013.
  • Funds reported $494M of Epizyme, Inc stock for Q1 2014, up 53% quarter-over-quarter.
  • 22 funds opened new Epizyme, Inc positions in Q1 2014 and 6 closed out, a net change of +16 holders.
  • The largest Epizyme, Inc buyer in Q1 2014 was Fidelity Investments, an estimated $53.1M added.
  • The largest Epizyme, Inc seller in Q1 2014 was MPM Asset Management, an estimated $14.1M sold.

Based on aggregated 13F filings for Q1 2014.